In 2006, Blázquez et al. showed that activation of CB1 and CB2 leads to a reduction in growth, proliferation, and metastasis of melanoma cells, as well as neovascularisation of melanoma xenografts [81]. The gene discussed is CNR2; the disease is melanoma.